Abstract:Background: Many human diseases are associated with dysregulation of HDACs. HDAC6 exhibits deacetylase activity not only to histone protein but also to non-histone proteins such as α- tubulin, HSP90, cortactin, and peroxiredoxin. These unique functions of HDAC6 have gained significant attention in the medicinal chemistry community in recent years. Thus a great deal of effort has devoted to developing selective HDAC6 inhibitors for therapy with the hope to minimize the side effects caused by pan-HDAC inhibition. Objective: The review intends to analyze the structural feature of the scaffolds, to provide useful information for those who are interested in this field, as well as to spark the future design of the new inhibitors. Methods: The primary tool used for patent searching is SciFinder. All patents are retrieved from the following websites: the World Intellectual Property Organization (WIPO®), the United States Patent Trademark Office (USPTO®), Espacenet®, and Google Patents. The years of patents covered in this review are between 2016 and 2019. Results: Thirty-six patents from seventeen companies/academic institutes were classified into three categories based on the structure of ZBG: hydroxamic acid, 1,3,4-oxadiazole, and 1,2,4-oxadiazole. ZBG connects to the cap group through a linker. The cap group can tolerate different functional groups, including amide, urea, sulfonamide, sulfamide, etc. The cap group appears to modulate the selectivity of HDAC6 over other HDAC subtypes. Conclusion: Selectively targeting HDAC6 over other subtypes represents two fold advantages: it maximizes the pharmacological effects and minimizes the side effects seen in pan-HDAC inhibitors. Many small molecule selective HDAC6 inhibitors have advanced to clinical studies in recent years. We anticipate the approval of selective HDAC6 inhibitors as therapeutic agents in the near future.

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Structure, Functions and Selective Inhibitors of HDAC6

Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design

Novel Biphenyl-Based Scaffold As Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors: Identification, Development and Pharmacological Evaluation

Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity

Recent Development of Novel HDAC6 Isoform-Selective Inhibitors.

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives As HDAC6 Isoform-Selective Inhibitors.

Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery

Do Biological Activities of Selective Histone Deacetylase 6 (HDAC6) Inhibitors Rely on the Modification of Cap Group?

[Histone Deacetylase 6: Structure, Functions and Development of Selective Inhibitors].

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Inhibition of HDAC6 Activity in Kidney Diseases: a New Perspective

Design, Synthesis and Biological Evaluation of 3, 4-Disubstituted-imidazolidine-2, 5-Dione Derivatives As HDAC6 Selective Inhibitors

Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue

Synthesis and Structure‐activity Relationship of Thiol‐based Histone Deacetylase 6 Inhibitors

Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling

Medicinal Chemistry Insights into Novel HDAC Inhibitors: an Updated Patent Review (2012-2016).

Structure-Based Inhibitor Discovery Of Class I Histone Deacetylases (Hdacs)

Design, Synthesis, and Biological Evaluation of HDAC6 Inhibitors Based on Cap Modification Strategy.